Lifesci Capital Has Positive Outlook of PRAX FY2025 Earnings

by · The Cerbat Gem

Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) – Research analysts at Lifesci Capital lifted their FY2025 earnings estimates for Praxis Precision Medicines in a note issued to investors on Thursday, November 6th. Lifesci Capital analyst F. Brisebois now expects that the company will post earnings per share of ($12.99) for the year, up from their previous estimate of ($13.24). Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Praxis Precision Medicines’ current full-year earnings is ($10.22) per share. Lifesci Capital also issued estimates for Praxis Precision Medicines’ Q4 2025 earnings at ($3.06) EPS, Q1 2026 earnings at ($3.07) EPS, Q2 2026 earnings at ($3.06) EPS, Q3 2026 earnings at ($3.40) EPS, Q4 2026 earnings at ($3.39) EPS and FY2026 earnings at ($12.92) EPS.

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.45) by $0.09.

A number of other equities analysts also recently commented on the stock. Jefferies Financial Group restated a “buy” rating and issued a $300.00 target price (up from $65.00) on shares of Praxis Precision Medicines in a research note on Thursday, October 16th. HC Wainwright boosted their price objective on shares of Praxis Precision Medicines from $115.00 to $232.00 and gave the stock a “buy” rating in a research note on Thursday, October 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Praxis Precision Medicines in a report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $280.00 price target (up previously from $65.00) on shares of Praxis Precision Medicines in a research report on Friday, October 17th. Finally, Needham & Company LLC upped their price objective on shares of Praxis Precision Medicines from $80.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Praxis Precision Medicines currently has a consensus rating of “Moderate Buy” and a consensus price target of $240.00.

View Our Latest Stock Report on PRAX

Praxis Precision Medicines Stock Performance

Shares of NASDAQ PRAX opened at $167.89 on Monday. Praxis Precision Medicines has a fifty-two week low of $26.70 and a fifty-two week high of $206.71. The company has a market cap of $4.20 billion, a price-to-earnings ratio of -13.01 and a beta of 2.80. The business’s 50 day moving average price is $96.03 and its 200-day moving average price is $62.92.

Hedge Funds Weigh In On Praxis Precision Medicines

Hedge funds have recently bought and sold shares of the business. Woodline Partners LP lifted its holdings in Praxis Precision Medicines by 1,666.5% during the first quarter. Woodline Partners LP now owns 175,727 shares of the company’s stock valued at $6,655,000 after purchasing an additional 165,779 shares in the last quarter. Aberdeen Group plc increased its stake in shares of Praxis Precision Medicines by 143.5% during the second quarter. Aberdeen Group plc now owns 214,056 shares of the company’s stock worth $9,001,000 after purchasing an additional 126,153 shares in the last quarter. Assenagon Asset Management S.A. increased its stake in shares of Praxis Precision Medicines by 19.1% during the second quarter. Assenagon Asset Management S.A. now owns 604,298 shares of the company’s stock worth $25,411,000 after purchasing an additional 96,898 shares in the last quarter. Cormorant Asset Management LP raised its position in shares of Praxis Precision Medicines by 3.1% during the 1st quarter. Cormorant Asset Management LP now owns 1,745,000 shares of the company’s stock worth $66,083,000 after purchasing an additional 51,781 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in Praxis Precision Medicines by 6.7% in the 1st quarter. Rhumbline Advisers now owns 24,294 shares of the company’s stock valued at $920,000 after buying an additional 1,525 shares in the last quarter. Hedge funds and other institutional investors own 67.84% of the company’s stock.

About Praxis Precision Medicines

(Get Free Report)

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.

Featured Stories